UY25374A1 - Composiciones de apomorfina útiles en el tratamiento de disfunción sexual femenina - Google Patents
Composiciones de apomorfina útiles en el tratamiento de disfunción sexual femeninaInfo
- Publication number
- UY25374A1 UY25374A1 UY25374A UY25374A UY25374A1 UY 25374 A1 UY25374 A1 UY 25374A1 UY 25374 A UY25374 A UY 25374A UY 25374 A UY25374 A UY 25374A UY 25374 A1 UY25374 A1 UY 25374A1
- Authority
- UY
- Uruguay
- Prior art keywords
- amount
- sexual dysfunction
- female sexual
- treatment
- ampomorphine
- Prior art date
Links
- 206010057671 Female sexual dysfunction Diseases 0.000 title abstract 2
- VMWNQDUVQKEIOC-CYBMUJFWSA-N apomorphine Chemical compound C([C@H]1N(C)CC2)C3=CC=C(O)C(O)=C3C3=C1C2=CC=C3 VMWNQDUVQKEIOC-CYBMUJFWSA-N 0.000 title abstract 2
- 229960004046 apomorphine Drugs 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title 1
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 abstract 2
- 230000017531 blood circulation Effects 0.000 abstract 2
- 239000002552 dosage form Substances 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 229920000858 Cyclodextrin Polymers 0.000 abstract 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 abstract 1
- 239000001116 FEMA 4028 Substances 0.000 abstract 1
- 229930195725 Mannitol Natural products 0.000 abstract 1
- 206010028813 Nausea Diseases 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 229960005070 ascorbic acid Drugs 0.000 abstract 1
- 235000010323 ascorbic acid Nutrition 0.000 abstract 1
- 239000011668 ascorbic acid Substances 0.000 abstract 1
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 abstract 1
- 235000011175 beta-cyclodextrine Nutrition 0.000 abstract 1
- 229960004853 betadex Drugs 0.000 abstract 1
- 235000010355 mannitol Nutrition 0.000 abstract 1
- 239000000594 mannitol Substances 0.000 abstract 1
- 230000008693 nausea Effects 0.000 abstract 1
- 230000036470 plasma concentration Effects 0.000 abstract 1
- 230000001568 sexual effect Effects 0.000 abstract 1
- 230000000638 stimulation Effects 0.000 abstract 1
- ODLHGICHYURWBS-LKONHMLTSA-N trappsol cyclo Chemical compound CC(O)COC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)COCC(O)C)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1COCC(C)O ODLHGICHYURWBS-LKONHMLTSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Reproductive Health (AREA)
- Endocrinology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Emergency Medicine (AREA)
- Epidemiology (AREA)
- Gynecology & Obstetrics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Compounds Of Unknown Constitution (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
Abstract
Forma de dosificación sublingual para el mejoramiento de la disfunción sexual femenina, que comprende apomorfina o una sal de adición de ácido farmacéuticamente aceptable de la misma, contenida en una cantidad de 2 miligramos a 12 miligramos de ampomorfina, de modo que la cantidad útil sea suficiente para incrementar el flujo de sangre intraclitorial y el flujo sanguíneo de las paredes vaginales que se produce por estimulación de de dicha mujer, pero menos que la cantidad que provoca náuseas; la dosis puede también comprender una beta-ciclodextrina (más particularmente hidroxipropil-beta-ciclodextrina). La forma de dosificación también puede incluir manitol y ácido ascórbico. Se incluye en especial una dosificación que comprende ampomorfina o sal de adición de la misma en una cantidad suficiente para mantener la concentración del plasma entre 1 a 2 nanogramos por milímetro de plasma durante la actividad sexual.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US09/016,252 US5945117A (en) | 1998-01-30 | 1998-01-30 | Treatment of female sexual dysfunction |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UY25374A1 true UY25374A1 (es) | 1999-09-27 |
Family
ID=21776169
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UY25374A UY25374A1 (es) | 1998-01-30 | 1999-01-29 | Composiciones de apomorfina útiles en el tratamiento de disfunción sexual femenina |
Country Status (34)
| Country | Link |
|---|---|
| US (2) | US5945117A (es) |
| EP (1) | EP1056419A4 (es) |
| JP (1) | JP2002501875A (es) |
| KR (1) | KR20010040477A (es) |
| CN (1) | CN1250221C (es) |
| AR (1) | AR017976A1 (es) |
| AU (1) | AU752928B2 (es) |
| BG (1) | BG64667B1 (es) |
| BR (1) | BR9908038A (es) |
| CA (1) | CA2322289A1 (es) |
| CO (1) | CO4970819A1 (es) |
| CR (1) | CR5959A (es) |
| DZ (1) | DZ2714A1 (es) |
| GC (1) | GC0000096A (es) |
| GT (1) | GT199900013A (es) |
| HK (1) | HK1040901B (es) |
| HN (1) | HN1999000015A (es) |
| HU (1) | HUP0101268A3 (es) |
| IL (2) | IL137569A0 (es) |
| JO (1) | JO2085B1 (es) |
| MA (1) | MA26600A1 (es) |
| MX (1) | MXPA00007447A (es) |
| NO (1) | NO319821B1 (es) |
| NZ (1) | NZ506597A (es) |
| PA (1) | PA8467801A1 (es) |
| PE (1) | PE20000240A1 (es) |
| PL (1) | PL194350B1 (es) |
| SK (1) | SK11362000A3 (es) |
| TN (1) | TNSN99008A1 (es) |
| TR (1) | TR200002220T2 (es) |
| TW (1) | TW550069B (es) |
| UY (1) | UY25374A1 (es) |
| WO (1) | WO1999038467A1 (es) |
| ZA (1) | ZA99686B (es) |
Families Citing this family (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6395744B1 (en) * | 1994-04-22 | 2002-05-28 | Queen's University At Kingston | Method and compositions for the treatment or amelioration of female sexual dysfunction |
| US20020165122A1 (en) * | 1994-04-22 | 2002-11-07 | Heaton Jeremy P. W. | Method and compositions for the treatment or amelioration of female sexual dysfunction |
| US20050065161A1 (en) * | 1996-02-02 | 2005-03-24 | Nitromed, Inc. | Nitrosated and nitrosylated alpha-adrenergic receptor antagonist compounds, compositions and their uses |
| US6472425B1 (en) | 1997-10-31 | 2002-10-29 | Nitromed, Inc. | Methods for treating female sexual dysfunctions |
| US5945117A (en) * | 1998-01-30 | 1999-08-31 | Pentech Pharmaceuticals, Inc. | Treatment of female sexual dysfunction |
| AU2003204720B2 (en) * | 1998-05-29 | 2006-06-29 | Tap Pharmaceutical Products Inc. | Methods for the normalization of sexual response and amelioration of long term genital tissue degradation |
| WO1999066909A2 (en) * | 1998-06-22 | 1999-12-29 | Univ Kingston | Method and compositions for the treatment or amelioration of female sexual dysfunction |
| US20050245494A1 (en) * | 1999-07-01 | 2005-11-03 | 40 J's Llc | Methods to treat one or all of the defined etiologies of female sexual dysfunction |
| US20040254153A1 (en) * | 1999-11-08 | 2004-12-16 | Pfizer Inc | Compounds for the treatment of female sexual dysfunction |
| BR0005797A (pt) * | 2000-03-20 | 2001-10-16 | Abbott Lab | Métodos para o tratamento de disfunção sexual com apomorfina em nìveis de concentração plasmática especificados |
| AU2001255818A1 (en) | 2000-04-07 | 2001-10-23 | Tap Pharmaceutical Products Inc. | Apomorphine derivatives and methods for their use |
| DE60131644T2 (de) | 2000-05-09 | 2008-10-30 | Nitromed, Inc., Lexington | Infrarotthermographie und behandlung von sexuellen dysfunktionen |
| CA2417552C (en) | 2000-06-27 | 2014-05-13 | Qualilife Pharmaceuticals Inc. | Compositions and methods for treating females sexual response |
| US7223406B2 (en) | 2000-07-21 | 2007-05-29 | The Regents Of The University Of California | Methods and compositions for preventing and treating male erectile dysfunction and female sexual arousal disorder |
| EP1365794A2 (en) * | 2000-07-21 | 2003-12-03 | Lue, Tom | Prevention and treatment of sexual arousal disorders |
| US20020065286A1 (en) * | 2000-08-21 | 2002-05-30 | Davies Michael John | Treatment of wounds |
| SK7422003A3 (en) | 2000-11-15 | 2004-01-08 | Tap Pharmaceutical Prod Inc | Treatment of anti-depression drug-induced sexual dysfunction with apomorphine |
| AU2002226895B2 (en) * | 2000-11-22 | 2006-10-12 | Abbott Laboratories | Selective dopamine D4 receptor agonists for treating sexual dysfunction |
| KR20030074810A (ko) * | 2001-02-08 | 2003-09-19 | 파마시아 코포레이션 | 성 기능장애의 치료를 위한 신속-발현 약 |
| KR20050008658A (ko) * | 2002-03-19 | 2005-01-21 | 마이클 홀릭 | 아포모르핀의 글리코시드 및 오르토에스테르 글리코시드유도체들, 유사체들 및 그것의 용도 |
| US20030219696A1 (en) * | 2002-05-23 | 2003-11-27 | Moreland Gerald W. | Method and apparatus for preventing backflow in dental saliva evacuators |
| GB0219961D0 (en) | 2002-08-28 | 2002-10-02 | Pfizer Ltd | Oxytocin inhibitors |
| GB0221711D0 (en) * | 2002-09-19 | 2002-10-30 | Ardana Bioscience Ltd | Methods |
| US20040138291A1 (en) * | 2002-10-10 | 2004-07-15 | Adams Michael A. | Treatment of sexual dysfunction |
| CA2451267A1 (en) * | 2002-12-13 | 2004-06-13 | Warner-Lambert Company Llc | Pharmaceutical uses for alpha2delta ligands |
| AU2004228757A1 (en) * | 2003-04-14 | 2004-10-21 | Vectura Ltd | Pharmaceutical compositions comprising apomorphine for pulmonary inhalation |
| US20040204439A1 (en) * | 2003-04-14 | 2004-10-14 | Staniforth John Nicholas | Composition, device, and method for treating sexual dysfunction via inhalation |
| US7306812B2 (en) | 2003-05-09 | 2007-12-11 | Cephalon, Inc. | Dissolvable backing layer for use with a transmucosal delivery device |
| US7276246B2 (en) * | 2003-05-09 | 2007-10-02 | Cephalon, Inc. | Dissolvable backing layer for use with a transmucosal delivery device |
| GB0314054D0 (en) * | 2003-06-17 | 2003-07-23 | Pfizer Ltd | Amide derivatives as selective serotonin re-uptake inhibitors |
| US20050054688A1 (en) * | 2003-08-08 | 2005-03-10 | Pfizer Inc | Selective serotonin reuptake inhibitors in the treatment of disease |
| DE10338174A1 (de) * | 2003-08-20 | 2005-03-24 | Lts Lohmann Therapie-Systeme Ag | Transdermale Arzneimittelzubereitungen mit Wirkstoffkombinationen zur Behandlung der Parkinson-Krankheit |
| US7291640B2 (en) * | 2003-09-22 | 2007-11-06 | Pfizer Inc. | Substituted triazole derivatives as oxytocin antagonists |
| GB0409744D0 (en) * | 2004-04-30 | 2004-06-09 | Pfizer Ltd | Novel compounds |
| EA200601798A1 (ru) * | 2004-04-30 | 2007-04-27 | Уорнер-Ламберт Компани Ллс | Замещенные соединения морфолина для лечения расстройств центральной нервной системы |
| US20080214622A1 (en) * | 2005-03-21 | 2008-09-04 | Alan Daniel Brown | Substituted Triazole Derivatives As Oxytocin Antagonists |
| EP1863795B1 (en) * | 2005-03-21 | 2008-10-29 | Pfizer Limited | Substituted triazole derivatives as oxytocin antagonists |
| RU2406480C2 (ru) * | 2005-04-08 | 2010-12-20 | Озфарма Пти Лтд | Трансбуккальная система доставки |
| WO2007017752A1 (en) * | 2005-08-10 | 2007-02-15 | Pfizer Limited | Substituted triazole derivatives as oxytocin antagonists |
| US8349850B2 (en) * | 2006-03-28 | 2013-01-08 | Atir Holding S.A. | Heterocyclic compounds and uses thereof in the treatment of sexual disorders |
| US7800094B2 (en) * | 2007-06-11 | 2010-09-21 | Macronix International Co., Ltd. | Resistance memory with tungsten compound and manufacturing |
| ES2699077T3 (es) | 2009-06-12 | 2019-02-07 | Sunovion Pharmaceuticals Inc | Apomorfina sublingual |
| WO2011130608A1 (en) * | 2010-04-15 | 2011-10-20 | Life Science Enhancement Corporation | Methods and compositions for enhancing female sexual arousal and treating female sexual dysfunction |
| EA031156B1 (ru) | 2010-12-16 | 2018-11-30 | Суновион Фармасьютикалз Инк. | Сублингвальные пленки |
| CA2832822A1 (en) | 2011-04-10 | 2012-10-18 | Atir Holding S.A. | Heterocyclic compounds and uses thereof in the treatment of sexual disorders |
| EP2545905A1 (en) | 2011-07-11 | 2013-01-16 | Britannia Pharmaceuticals Limited | A new therapeutical composition containing apomorphine as active ingredient |
| WO2016172095A1 (en) | 2015-04-21 | 2016-10-27 | Cynapsus Therapeutics, Inc. | Methods of treating parkinson's disease by administration of apomorphine to an oral mucosa |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4521421A (en) * | 1983-09-26 | 1985-06-04 | Eli Lilly And Company | Treatment of sexual dysfunction |
| JPH07506823A (ja) * | 1992-05-18 | 1995-07-27 | スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー | 記憶障害，性的機能不全およびパーキンソン氏病の治療のためのインドロン誘導体の使用 |
| US5565466A (en) * | 1993-08-13 | 1996-10-15 | Zonagen, Inc. | Methods for modulating the human sexual response |
| ES2143049T3 (es) * | 1994-04-22 | 2000-05-01 | Pentech Pharmaceuticals Inc | Formas sublinguales de dosificacion que contienen apomorfina y su uso para el tratamiento de la disfuncion erectil. |
| US5562917A (en) * | 1994-12-23 | 1996-10-08 | Pentech Pharmaceuticals, Inc. | Transdermal administration of apomorphine |
| US5624677A (en) * | 1995-06-13 | 1997-04-29 | Pentech Pharmaceuticals, Inc. | Controlled release of drugs delivered by sublingual or buccal administration |
| US5945117A (en) * | 1998-01-30 | 1999-08-31 | Pentech Pharmaceuticals, Inc. | Treatment of female sexual dysfunction |
-
1998
- 1998-01-30 US US09/016,252 patent/US5945117A/en not_active Expired - Fee Related
-
1999
- 1999-01-21 TN TNTNSN99008A patent/TNSN99008A1/fr unknown
- 1999-01-28 CA CA002322289A patent/CA2322289A1/en not_active Abandoned
- 1999-01-28 TR TR2000/02220T patent/TR200002220T2/xx unknown
- 1999-01-28 NZ NZ506597A patent/NZ506597A/en unknown
- 1999-01-28 JO JO19992085A patent/JO2085B1/en active
- 1999-01-28 AU AU25644/99A patent/AU752928B2/en not_active Ceased
- 1999-01-28 PL PL99342062A patent/PL194350B1/pl unknown
- 1999-01-28 SK SK1136-2000A patent/SK11362000A3/sk unknown
- 1999-01-28 CR CR5959A patent/CR5959A/es not_active Application Discontinuation
- 1999-01-28 HU HU0101268A patent/HUP0101268A3/hu unknown
- 1999-01-28 ZA ZA9900686A patent/ZA99686B/xx unknown
- 1999-01-28 HK HK02101988.0A patent/HK1040901B/zh not_active IP Right Cessation
- 1999-01-28 HN HN1999000015A patent/HN1999000015A/es unknown
- 1999-01-28 WO PCT/US1999/001776 patent/WO1999038467A1/en not_active Ceased
- 1999-01-28 IL IL13756999A patent/IL137569A0/xx active IP Right Grant
- 1999-01-28 KR KR1020007008333A patent/KR20010040477A/ko not_active Ceased
- 1999-01-28 BR BR9908038-9A patent/BR9908038A/pt not_active Application Discontinuation
- 1999-01-28 EP EP99905497A patent/EP1056419A4/en not_active Withdrawn
- 1999-01-28 JP JP2000529203A patent/JP2002501875A/ja not_active Withdrawn
- 1999-01-28 CN CNB998044423A patent/CN1250221C/zh not_active Expired - Fee Related
- 1999-01-28 MX MXPA00007447A patent/MXPA00007447A/es not_active IP Right Cessation
- 1999-01-29 MA MA25442A patent/MA26600A1/fr unknown
- 1999-01-29 AR ARP990100389A patent/AR017976A1/es not_active Application Discontinuation
- 1999-01-29 TW TW088101384A patent/TW550069B/zh not_active IP Right Cessation
- 1999-01-29 CO CO99005067A patent/CO4970819A1/es unknown
- 1999-01-29 UY UY25374A patent/UY25374A1/es not_active Application Discontinuation
- 1999-01-29 PA PA19998467801A patent/PA8467801A1/es unknown
- 1999-01-29 PE PE1999000067A patent/PE20000240A1/es not_active Application Discontinuation
- 1999-01-30 DZ DZ990015A patent/DZ2714A1/xx active
- 1999-01-31 GC GCP199973 patent/GC0000096A/xx active
- 1999-07-02 US US09/345,009 patent/US6193992B1/en not_active Expired - Fee Related
-
2000
- 2000-07-27 NO NO20003845A patent/NO319821B1/no unknown
- 2000-07-27 IL IL137569A patent/IL137569A/en unknown
- 2000-08-28 BG BG104715A patent/BG64667B1/bg unknown
-
2001
- 2001-07-20 GT GT199900013A patent/GT199900013A/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UY25374A1 (es) | Composiciones de apomorfina útiles en el tratamiento de disfunción sexual femenina | |
| US6465512B2 (en) | Leukemic cell growth inhibiting method | |
| MX9605089A (es) | Incremento de la biodisponibilidad de compuestos biologicamente activos mediante la union a derivados de polipirrolcarboxamidonaftaleno. | |
| AR100291A2 (es) | Composición catártica | |
| ES2093918T3 (es) | Dentifrico no irritante. | |
| CO5271759A1 (es) | Formulacion en solucion que contiene una mezcla de disolventes | |
| EP0151989A3 (en) | Means for the treatment of cardiac diseases | |
| CO5590913A2 (es) | Terapia de combinacion antivirica | |
| MD1688F2 (en) | Benzothiophene, benzofuran and indolethiazepinons, oxazepinons and diazepinons, pharmaceutical composition, method of inhibiting the leucocytes adherence to the endothelial cells for inflammatory diseases treatment and method of treatment of the mammals affected by the HIV infection | |
| AR015744A1 (es) | Uso de dexmedetomidina para sedacion en terapia intensiva | |
| PE33396A1 (es) | Composicion para el tratamiento del ansia de nicotina y/o los sintomas de abstinencia de fumar | |
| ES2108240T3 (es) | Derivados de tiosemicarbazona de 2-formilpiridina, su preparacion y su uso como agentes antitumor. | |
| ES2087623T3 (es) | Derivados de bencimidazol como agente antimicrobiano contra campylobacter pylon. | |
| KR890004693A (ko) | 남성형 대머리와 원치 않는 모발의 성장을 치료하는 방법 | |
| MX9205568A (es) | Composicion farmaceutica que contiene cantidades de 5-amino-1beta-d-ribofuranosil-imidazol-4-carboxamida. | |
| CO4960654A1 (es) | Metodo para el tratamiento de enfermedades fisiologicas relacionadas con el uso o con las secuelas provocadas por el uso de la cocaina u otros estimulantes psicomotores | |
| AR041069A1 (es) | Composicion de tolterodina liquida oral | |
| ES2115571T3 (es) | Uso de polisulfato de pentosana para la resolucion de cicatrices en enfermedades vasculares progresivas cronicas. | |
| ES2105923B1 (es) | Composiciones para el tratamiento de una infeccion y una enfermedad causadas por el virus de la hepatitis b (hbv). | |
| CO5021217A1 (es) | Composiciones estables de mitoxantrona, procedimietno para prepararlas; utilizacion de dichas composiciones y medica- mentos que incluyen dichas soluciones para el tratamiento de enfermedades cancerosas | |
| ES2086528T3 (es) | Nuevos compuestos biciclicos sustituidos con amino. | |
| ES2039460T3 (es) | Un procedimiento para producir una solucion inyectable de glicosido de antraciclina. | |
| RU2003104017A (ru) | Ингибиторы тромбина, содержащие аминоизохинолиновую группу | |
| IS6555A (is) | Meðferð með aðskildum skömmtum sem hafa æðaskaðandi virkni | |
| ES2111013T3 (es) | Una composicion profilactica/terapeutica que contiene ws7622a para evitar o tratar la coagulacion intravascular diseminada, la enfermedad infecciosa cronica del tracto respiratorio o la bronquitis cronica. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 109 | Application deemed to be withdrawn |
Effective date: 20120117 |